Corcept Therapeutics (NASDAQ:CORT) Full Year 2022 Results
Key Financial Results
Revenue: US$401.9m (up 9.8% from FY 2021).
Net income: US$101.3m (down 10.0% from FY 2021).
Profit margin: 25% (down from 31% in FY 2021). The decrease in margin was driven by higher expenses.
EPS: US$0.95 (down from US$0.97 in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Corcept Therapeutics EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.9%.
Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Pharmaceuticals industry in the US.
The company's shares are down 9.6% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Corcept Therapeutics' balance sheet and an in-depth analysis of the company's financial position.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here